DNIB0600A

DNIB0600A Uses, Dosage, Side Effects, Food Interaction and all others data.

DNIB0600A is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).

Trade Name DNIB0600A
Generic Lifastuzumab vedotin
Lifastuzumab vedotin Other Names DNIB0600A, Lifastuzumab vedotin
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
DNIB0600A
DNIB0600A

Innovators Monograph

You find simplified version here DNIB0600A

*** Taking medicines without doctor's advice can cause long-term problems.
Share